Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:APGN

Apexigen (APGN) Stock Price, News & Analysis

About Apexigen Stock (NASDAQ:APGN)

Key Stats

Today's Range
$0.39
$0.39
50-Day Range
$0.36
$0.44
52-Week Range
$0.33
$8.28
Volume
N/A
Average Volume
967,731 shs
Market Capitalization
$9.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.

Receive APGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apexigen and its competitors with MarketBeat's FREE daily newsletter.

APGN Stock News Headlines

Musk warns humanity: “Obsolete”
The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.
APG SGA S.A.
See More Headlines

APGN Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Apexigen investors own include Sunworks (SUNW), Applied DNA Sciences (APDN), Ginkgo Bioworks (DNA), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Mullen Automotive (MULN) and Ambrx Biopharma (AMAM).

Company Calendar

Today
10/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APGN
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Net Income
$-32,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.09) per share

Miscellaneous

Free Float
20,088,000
Market Cap
$9.57 million
Optionable
Not Optionable
Beta
3.60
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:APGN) was last updated on 10/24/2024 by MarketBeat.com Staff
From Our Partners